Breast Cancer News

CHICAGO — Trastuzumab deruxtecan extended PFS compared with standard chemotherapy for certain patients with pretreated breast cancer, according to findings presented at ASCO Annual Meeting.

Participation in cancer-related clinical trials could increase dramatically if researchers screened and recruited individuals using routine care patient-reported outcomes, according to results published in JAMA Oncology.

Tremendous progress has been made in the treatment landscape for HER2-positive breast cancer that has significantly altered and improved the outlook for this patient population.

A study assessing the efficacy of pembrolizumab met a key secondary endpoint of extending OS, in combination with chemotherapy, among patients with high-risk early-stage triple-negative breast cancer, according to the agent’s manufacturer.

CHICAGO — The majority of young breast cancer survivors who attempted pregnancy became pregnant, according to prospective study results scheduled for presentation at ASCO Annual Meeting.

Active cancer treatment is associated with increased risk for sudden cardiac death, especially among patients younger than 74 years old and those with a history of heart failure, results from a retrospective study showed.

Most childhood cancer survivors are not up to date on guideline-recommended screening for late effects of cancer treatment or second malignancies, according to study results.

An analysis of global online conversations among health care professionals on social media in April revealed tremendous enthusiasm about FDA approval of a treatment for adults with advanced HER2-positive solid tumors.

Patients participating in clinical trials for anticancer drugs do not gain a survival benefit compared with individuals who received routine care, according to study results published in JAMA.

The prospect of screening for multiple cancer types simultaneously through a blood draw or other simple methods has generated tremendous excitement.